Don’t Consider Sotagliflozin a Diabetes Med
July 2023
New Rx sotagliflozin (Inpefa) will join dapagliflozin (Farxiga), empagliflozin (Jardiance), and other SGLT2 inhibitors.
But sotagliflozin is the only SGLT2 inhibitor NOT yet approved for treating type 2 diabetes.
It’s currently only approved to reduce the risk of heart failure urgent care visits and hospitalizations and cardiovascular death...in certain adults with OR without diabetes.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote